Legend Biotech Corporation (LEGN)

NASDAQ: LEGN · IEX Real-Time Price · USD

43.98

+0.24 (0.55%)

At close: May 1, 2024, 4:00 PM

44.75

+0.77 (1.75%)

After-hours: May 1, 2024, 7:21 PM EDT

Legend Biotech Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018
Market Capitalization	8,000	10,938	7,705	6,774	3,643	-	-
Market Cap Growth	-	41.96%	13.75%	85.96%	-	-	-
Enterprise Value	7,020	9,958	6,963	6,013	3,140	-153	-212
PE Ratio	-21.11	-21.11	-17.26	-16.78	-13.67	-	-
PS Ratio	28.06	38.36	65.85	98.42	48.57	-	-
PB Ratio	6.39	8.74	10.35	8.84	13.00	-	-
P/FCF Ratio	-23.76	-23.76	-30.55	-33.95	-14.03	-	-
P/OCF Ratio	-24.89	-24.89	-36.68	-33.95	-15.61	-	-
EV/Sales Ratio	24.62	34.92	59.51	87.37	41.86	-2.55	-4.32
EV/EBITDA Ratio	-20.84	-20.84	-16.72	-15.32	-10.67	1.26	-1582.97
EV/EBIT Ratio	-19.98	-19.98	-16.01	-14.80	-10.33	1.20	138.28
EV/FCF Ratio	-21.63	-21.63	-27.60	-30.14	-12.10	1.48	-0.74
Debt / Equity Ratio	0.26	0.26	0.38	0.16	0.01	-0.05	0.50
Debt / EBITDA Ratio	-0.69	-0.69	-0.68	-0.31	-0.01	-0.05	32.22
Debt / FCF Ratio	-0.71	-0.71	-1.13	-0.62	-0.01	-0.06	0.02
Quick Ratio	6.51	6.51	3.45	4.08	3.61	1.48	1.52
Current Ratio	6.92	6.92	3.69	4.14	3.68	1.62	2.05
Asset Turnover	0.17	0.17	0.10	0.08	0.15	0.17	-
Interest Coverage	-22.87	-22.87	-40.29	-451.44	-72.24	-569.94	-18.71
Return on Equity (ROE)	-44.60%	-44.60%	-59.10%	-105.00%	-338.50%	177.90%	-
Return on Assets (ROA)	-30.40%	-30.40%	-36.40%	-47.20%	-52.80%	-28.30%	-
Return on Capital (ROIC)	-24.31%	-24.31%	-43.35%	-43.98%	-78.89%	108.64%	-11.82%
Earnings Yield	-6.48%	-4.74%	-5.79%	-5.96%	-7.31%	-	-
FCF Yield	-5.75%	-4.21%	-3.27%	-2.95%	-7.13%	-	-
Buyback Yield / Dilution	-10.71%	-10.71%	-12.91%	-19.21%	-18.15%	-	-
Total Shareholder Return	-10.71%	-10.71%	-12.91%	-19.21%	-18.15%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).